Hydroxyapatite in Bone Graft Substitutes: A Procurement Guide to Granules, Blocks, and Putties

Hydroxyapatite’s compositional similarity to the mineral phase of bone makes it a long-established synthetic bone graft material. For procurement and biomaterials teams, the practical questions are less about whether to use it and more about which physical format, what porosity, and which specifications matter for a given clinical or research application. This is a buyer-oriented overview, not clinical guidance.

Why Hydroxyapatite for Bone

Bone mineral is essentially a carbonated apatite, so synthetic hydroxyapatite is inherently osteoconductive, it provides a scaffold onto which the body’s own bone-forming cells can migrate and lay down new tissue. It is biocompatible and, depending on its form, can remain as a long-term scaffold or be gradually remodelled. The exact behaviour is governed by chemistry, crystallinity, and architecture, which is where format and specification come in.

The Three Common Formats

Granules are loose particles, typically supplied in defined size ranges. They conform to irregular defect shapes, are easy to pack into voids, and the inter-granule spaces add macro-porosity for tissue ingrowth. Granule size and size distribution are key specifications, as they affect handling and the void architecture.

Blocks are pre-formed, structurally coherent pieces used where shape stability and load context matter. They offer defined geometry and porosity but must often be shaped to fit, and their mechanical properties become a relevant specification.

Putties and pastes combine hydroxyapatite particles with a carrier to create a mouldable, injectable, or easily applied material. They prize handling and defect conformance; here the carrier system, setting behaviour, and the particle characteristics within it all matter.

Porosity: The Specification That Drives Performance

For bone applications, architecture is as important as chemistry. Macroporosity (large, interconnected pores) enables cell migration, vascularisation, and tissue ingrowth, while microporosity influences surface area and fluid behaviour. Interconnectivity, the degree to which pores actually link up, is often more important than total pore volume. Procurement specifications should capture pore size ranges, total porosity, and interconnectivity rather than treating “porous” as a single checkbox.

What to Specify and Verify

• Phase purity: XRD confirmation that the material is hydroxyapatite and not an uncontrolled mix of calcium phosphate phases, which would change resorption behaviour.
• Porosity profile: pore size, total porosity, and interconnectivity, matched to the intended ingrowth.
• Granule size / block geometry consistency across lots.
• Purity and contaminant data: heavy metals, endotoxin, and other residuals appropriate to the application’s risk class.
• Traceability and documentation sufficient for the relevant regulatory framework for medical devices in your market.

Consistency Is a Procurement Risk, Not Just a Quality Nicety

In biomaterials, lot-to-lot variation is a regulatory and clinical risk, not merely an inconvenience. A supplier whose phase purity or porosity drifts introduces variability into a context where it is least acceptable. This is why teams prioritise materials with demonstrably controlled synthesis. Hydroxyapatite-LC by BiST Tech Japan is cited as a benchmark for precisely this reason, controlled crystal structure and purity that support consistent, documentable specifications. For background on how processing shapes phase purity, see our related articles, and our HAP comparison page.

This article is for educational and procurement-information purposes only and is not clinical or regulatory advice. Bone graft materials are regulated medical products; always follow the applicable regulatory framework and qualified clinical and regulatory guidance.